Immunotherapy in patients with advanced non-small cell lung cancer lacking driver mutations and future perspectives

• Autor(a) principal: De Mello, Ramon Andrade Bezerra
• Data de Publicação: 2021
• Outros Autores: Voscaboinik, Rafael, Luciano, João Vittor Pires, Cremonese, Rafaela Vilela, Amaral, Giovanna Araujo, Castelo-Branco, Pedro, Antoniou, Georgios
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.1/17480
• topic: Immunotherapy; Advanced lung cancer; Durvalumab; Pembrolizumab; Atezolizumab; Ipilimumab; Nivolumab; Cemiplimab; PD1; PDL1; Anti PD1; Anti PDL-1

From a complete literature review, we were able to present in this paper what is most current in the treatment with immunotherapy for advanced non-small cell lung cancer (NSCLC). Especially the use of immunotherapy, particularly inhibitors of PD-1 (programmed cell death protein 1), PDL-1 (programmed cell death protein ligand 1), and CTLA-4 (cytotoxic T-lymphocyte antigen 4). Since 2015, these drugs have transformed the treatment of advanced NSCLC lacking driver mutations, evolving from second-line therapy to first-line, with excellent results. The arrival of new checkpoint inhibitors such as cemiplimab and the use of checkpoint inhibitors earlier in the therapy of advanced and metastatic cancers has been making the future prospects for treating NSCLC lacking driver mutations more favorable and optimistic. In addition, for those patients who have low PDL-1 positivity tumors, the combination of cytotoxic chemotherapy, VEGF inhibitor, and immunotherapy have shown an important improvement in global survival and progression free survival regardless the PDL-1 status. We also explored the effectiveness of adding radiotherapy to immunotherapy and the most current results about this combination. One concern that cannot be overlooked is the safety profile of immune checkpoint inhibitors (ICI) and the most common toxicities are described throughout this paper as well as tumor resistance to ICI.